A confirmation study of the inhibitory effect of blood glucose increasing by consumption of the test drink
- Conditions
- Healthy adult
- Registration Number
- JPRN-UMIN000036979
- Lead Sponsor
- CPCC Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1) Subjects who are being received treatment and/or medication when informed consent. 2) Subjects who are not able to quit intake medicine, food for specific health, functional food and/or supplement having a possibility of affecting blood glucose level during test period. 3) Females who are pregnant or lactating, and females who could become pregnant or lactating during test period. 4) Subjects who have previous and/or current medical history of serious disease (e.g., heart, liver, kidney, digestive organ). 5) Subjects who excessive alcohol intake. 6) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. 7) Subjects who excessive alcohol intake. 8) Subjects who have weak digestive organ and/or have tendency of diarrhea. 9) Subjects who show more than 6.5 % in HbA1c level at preliminary test. 10) Subjects who show more than 160 mg/dL in fasting blood glucose level measured by glucose sensor at preliminary test. 11) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. 12) Subjects who donated over 200 mL blood and/or blood components within the last one month to the current study. 13) Subjects who donated over 400mL blood and/or blood components within the last three months to the current study. 14) Females who donated over 400mL blood and/or blood components within the last four months to the current study. 15) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 16) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve months are adding to the planned sampling amounts of this study. 17) Others they have been determined ineligible by principal investigator or sub-investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method *Area under the concentration time curve of blood glucose *Area under the concentration time curve of blood insulin
- Secondary Outcome Measures
Name Time Method *Area under the concentration time curve of blood triglyceride *Blood glucose level of each measuring point *Blood insulin level of each measuring point *Blood triglyceride level of each measuring point *Cmax of blood glucose level *Tmax of blood glucose level *Cmax of blood insulin level *Tmax of blood insulin level *Cmax of blood triglyceride level *Tmax of blood triglyceride level *The incidence of side effects and/or adverse events